| Outcome Measures: |
Primary: Area under the acetaminophen plasma concentration-time curve, From time 0 to 24 hours after a single dose.|Maximum observed acetaminophen concentration, From time 0 to 24 hours after a single dose.|Time of maximum observed acetaminophen concentration, From time 0 to 24 hours after a single dose.|Area under the metformin plasma concentration-time curve, From time 0 to 12 hours after the last of 7 repeated doses.|Area under the S-warfarin plasma concentration-time curve, From time 0 to 168 hours after a single dose.|Area under the atorvastatin plasma concentration-time curve, From time 0 to 72 hours after a single dose.|Area under the digoxin plasma concentration-time curve, From time 0 to 120 hours after a single dose. | Secondary: Area under the concentration versus time curve of acetaminophen from 0 to infinity, Start of treatment up to 168 hours.|Apparent volume of distribution of acetaminophen, Start of treatment up to 168 hours.|Time of maximum observed metformin concentration after 3.5 days of treatment, Start of Treatment up to 30 hours.|Clearance of metformin after 3.5 days of treatment, Start of Treatment up to 30 hours.|Apparent volume of distribution of metformin after 3.5 days of treatment, Start of Treatment up to 30 hours.|Time of maximum observed S-warfarin concentration, Start of Treatment up to 168 hours.|Clearance of S-warfarin, Start of Treatment up to 168 hours.|Apparent volume of distribution of S-warfarin, Start of Treatment up to 168 hours.|Time of maximum observed atorvastatin (and its active metabolites) concentration, Start of Treatment up to 72 hours.|Clearance of atorvastatin (and its active metabolites), Start of Treatment up to 72 hours.|Time of maximum observed digoxin concentration, Start of Treatment up to 120 hours.|Maximum observed digoxin concentration, Start of Treatment up to 120 hours.|Clearance of digoxin, Start of Treatment up to 120 hours.|Apparent volume of distribution of digoxin, Start of Treatment up to 120 hours.|Time of maximum observed HRS9532 concentration, Start of Treatment up to 168 hours.|Maximum observed HRS9531 concentration, Start of Treatment up to 168 hours.|Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration, Start of Treatment up to 168 hours.|Area under the concentration versus time curve of HRS9531 from 0 to infinity, Start of Treatment up to 168 hours.|Incidence and severity of adverse events, Screening period up to 117 days.
|
